You are not alone.
Whether you are trying to explain the impacts of your disease to your healthcare team, fill your prescription, get a new treatment option covered by insurance, explain to your family or friends what it’s like living with psoriasis or psoriatic arthritis, or get supports in the workplace, we are here for you.
Patients’ experiences and perspectives should be shared with - and heard by - the people who make decisions affecting their lives. CAPP actively works with governments, private plans, healthcare providers, pharmaceutical companies, and researchers to better understand the challenges and barriers that psoriasis and psoriatic arthritis patients face.
Advocating on behalf of people impacted by psoriasis and psoriatic arthritis in Canada is one of CAPP’s strategic priorities. Learn more about how we do this.
Filling your prescription
If you have had trouble getting your prescription filled or renewed because the pharmacy cannot get in more of the drug, please let us know. CAPP shares this information with the federal drug shortages program and encourages them to take action to address the shortage.
Accessing New Treatments
Patient input submissions
When a new drug for psoriasis or psoriatic arthritis comes to patients in Canada, it must be reviewed in the context of other drugs available for these diseases if the manufacturer wants it to be listed on a public drug formulary. The Quebec government has its own health technology assessment (HTA), done by the Institut national d’excellence en santé et en services sociaux (INESSS). All other government drug plans in Canada refer to the HTA done by the Canadian Agency for Drugs and Technologies in Health (CADTH).
As part of these processes, patients are invited to share their experiences living with the disease, how helpful they find existing treatments, their treatment goals, and their experience with the new drug (if they have tried it) or their expectations of it (if they have not). Some provinces (BC, Ontario) have their own HTA processes. CAPP has provided patient input submissions for many new drugs :
- Ilumya (tildrakizumab) for treatment of plaque psoriasis (INESSS, February 2021)
- Duobrii (halobetasol propionate and tazarotene) for moderate to severe plaque psoriasis (INESSS, April 2020)
- Cimzia (certolizumab pegol) for treatment of moderate to severe plaque psoriasis (INESSS, March 2020)
- Duobrii (halobetasol propionate and tazarotene) for moderate to severe plaque psoriasis (CADTH, February 2020)
- Rinvoq (upadacitinib) for psoriatic arthritis (INESSS, February 2021
- Rinvoq (upadacitinib) for psoriatic arthritis (CADTH, January 2021)
Position statement on biosimilars
CAPP supports efforts to help health systems across Canada save money and improve patients’ access to new therapies for psoriasis and psoriatic arthritis. Biosimilars can reduce costs to patients and the health system but policies designed to increase their use risk reducing treatment options for our patients. The goal of any biosimilar policy must be to improve health outcomes and quality of life, as defined by patients. CAPP urges drug plans to respect shared decision-making between a patient and their physician as they explore these policy options.
Rare disease drug strategy
CAPP contributed to the submission from the Best Medicines Coalition as part of the federal government’s consultation on a new rare disease drug strategy in January - March 2021.